Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome. — CFSMEATLAS
This study looked at 84 women with connective tissue disorders (HSD/h-EDS) to understand how much autonomic nervous system problems they experience and how these affect their quality of life. The researchers found that these women had severe autonomic symptoms, with nearly 60% also having POTS and about 26% having ME/CFS. Overall, their quality of life was significantly worse than patients with other serious conditions like multiple sclerosis or rheumatoid arthritis.
Why It Matters
ME/CFS affects over one-quarter of this HSD/h-EDS cohort, highlighting an important comorbidity overlap that clinicians should recognize. The severe autonomic dysfunction documented here provides objective evidence that HSD/h-EDS patients with ME/CFS experience significant physiological burden beyond fatigue alone. Understanding these interconnected conditions may help improve diagnosis, symptom management, and quality-of-life outcomes for ME/CFS patients with underlying connective tissue disorders.
Observed Findings
Mean COMPASS-31 autonomic dysfunction score was 54.45 (range 18.79-80.93), indicating severe dysfunction that exceeded comparison groups with MS, diabetic neuropathy, scleroderma, and psoriatic arthritis.
Mean SF-36 quality of life score was 32.38 (SD=22.91), worse than in patients with POTS, MS, rheumatoid arthritis, and lupus.
26.2% (n≈22) of the 84 participants reported physician-diagnosed ME/CFS.
25% of the cohort met criteria for the clinical triad of HSD/h-EDS, POTS, and MCAS simultaneously.
Inferred Conclusions
Women with HSD/h-EDS experience severe autonomic dysfunction that substantially exceeds that documented in other multisystemic diseases, contributing to poor quality of life outcomes.
The high prevalence and clustering of POTS, MCAS, and ME/CFS in this population suggests shared pathophysiological mechanisms or risk factors warranting further investigation.
Autonomic symptom burden and comorbid conditions are major drivers of quality-of-life impairment in HSD/h-EDS, underscoring the need for multisystem clinical approaches.
Remaining Questions
What specific autonomic dysfunctions (e.g., orthostatic intolerance, sudomotor dysfunction, cardiovascular dysregulation) most strongly correlate with ME/CFS in this population?
What This Study Does Not Prove
This study does not establish causality between HSD/h-EDS and ME/CFS, nor does it clarify whether autonomic dysfunction drives ME/CFS symptoms or vice versa. The cross-sectional design captures a single time point and cannot determine the temporal relationship between condition onsets. The all-female, physician-diagnosed cohort may not represent all HSD/h-EDS presentations, limiting generalizability to other populations.
Does the severity of connective tissue laxity predict the development or severity of ME/CFS and autonomic dysfunction in HSD/h-EDS?
Are the autonomic symptoms in HSD/h-EDS-associated ME/CFS responsive to treatments targeting either condition, and do interventions differ from isolated ME/CFS?
What is the temporal relationship between HSD/h-EDS onset, POTS, MCAS, and ME/CFS diagnosis, and does order of diagnosis affect clinical outcomes?